ArticleClinical and translational science2021

An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.

Astrid De Meulenaere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.